The implications and management of drug interactions with itraconazole, fluconazole and terbinafine

Dermatology

Volumn 201, Issue 3, 2000, Pages 196-203

  Shear, Neil ^a,b,f   Drake, Lynn ^c   Gupta, Aditya K ^b   Lambert, Julien ^d   Yaniv, Ron ^e  

^a Departments of Medicine and Pharmacology   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Department of Dermatology ^*  (Belgium)

^e SHEBA MEDICAL CENTER   (Israel)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Drug interactions; Fluconazole; Itraconazole; Safety; Terbinafine

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CENTRAL STIMULANT AGENT; DIURETIC AGENT; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; TERBINAFINE; TUBERCULOSTATIC AGENT;

ANAMNESIS; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; HUMAN; MYCOSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0033712378     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018488     Document Type: Article

References (45)

1. Mycological and clinical evalution of griseofulvin for chronic onychomycosis
2. Treatment of onychomycosis: Traditional approaches
3. Treatment of dermatomycoses and onychomycoses: State of the art
4. Update on the safety of itraconazole pulse therapy in onychomycosis
5. Onychomycosis: Going for cure
6. Mode of action studies: Basis for the search of new antifungals
7. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial myocses
8. Update: Clinically significant cytochrome P-450 drug interactions
9. Update on drug interactions with azole antifungal agents
10. Drug interactions with itraconazole, fluconazole and terbinafine, and their management
11. Recent advances: The cytochrome P450 enzymes
12. Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics
13. Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity
14. Influence of liver function on drug deposition
15. Possible pharmacokinetic interaction with quinidine: Ciprofloxacin or metronidazole?
16. Drug interactions with itraconazole, fluconazole, and terbinafine and thier management
17. Syncope and cardiac arrhythmia due to interaction between itraconazole and terfenadine
18. Torsades de pointes after terfenadine-itraconazole interaction
19. Cisapride and fatal arrhythmia
20. Intraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
21. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
22. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
23. Potentiation of action of warfarin by intraconazole
24. Interaction of cyclosporin and itraconazole
25. Time course of cyclosporin/itraconazole interaction
26. FK506 (tacrolimus) metabolism by rat microsomes and its inhibition by other drugs
27. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450 drug interactions, and interindividual variability
28. Itraconazole interacts with felodipine
29. Peripheral oedema due to nifedipine-itraconazole interaction: A case report
30. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole
31. Protein binding of itraconazole and fluconazole in patients with chronic renal failure
32. 2 blockers (abstract)
33. Safety of itraconazole in diabetic patients
34. Pharmacokinetics and drug disposition: The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans
35. Interaction between cyclosporine and fluconazole in renal allgraft recipients
36. Interaction of fluconazole with cyclosporin A
37. Fluconazole and phenytoin: A predictable interaction
38. Case report: Potentiation of warfarin by fluconazole
39. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
40. Terbinafine for onychomycosis
41. Investigation of terbinafine as a CYP2D6 inhibitor in vivo
42. Potential inhibition of cytochrome P450 2D6-mediated dextromethyorphan O-demethylation by terbinafine
43. Nortriptyline intoxication induced by terbinafine
44. Interaction between terbinafine and warfarin
45. Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers